Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Public ClinicalTrials.gov record NCT07908316. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Randomized, Double-blind, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Maridebart Cafraglutide After Switching From Glucagon-like Peptide-1 Receptor Agonists in Participants Living With Overweight or Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.
Study identification
- NCT ID
- NCT07908316
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2026 (Estimated)
- Primary completion
- Dec 20, 2027 (Estimated)
- Completion
- Feb 25, 2028 (Estimated)
- Last update posted
- Nov 2, 2026
2026 – 2028
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Research Center | Phoenix | Arizona | 85053 | Recruiting |
| Catalina Research Institute LLC (CRI) - Montclair | Montclair | California | 91763 | Recruiting |
| Fortrea Clinical Research Unit - Daytona Beach | Daytona Beach | Florida | 32117-5116 | Recruiting |
| AGA Clinical Trials | Hialeah | Florida | 33012-3437 | Recruiting |
| K2 Medical Research Orlando | Maitland | Florida | 32751-7240 | Recruiting |
| The Alliance for Multispecialty Research - Lexington | Lexington | Kentucky | 40509 | Recruiting |
| Alliance for Multispecialty Research - Knoxville | Knoxville | Tennessee | 37920-1534 | Recruiting |
| Fortrea Clinical Research Unit - Dallas | Dallas | Texas | 75247-4968 | Recruiting |
| Fortrea Clinical Research Unit Inc. - Madison | Madison | Wisconsin | 53704-2526 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07908316, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 2, 2026 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07908316 live on ClinicalTrials.gov.